Abingworth — 2018 Investments

4 investments dated 2018 · listed companies and verified rows first · show all

Stridebiostridebio.com inSeries A · Jun 2018 · $16M

StrideBio develops gene therapies based on its STRIVE AAV capsid platform, targeting people with life-threatening diseases.

BiotechHealthtechDurham, US

Aravind Asokan(Director)inMavis Abjandje-McKenna(Director)Richard Smith(Executive Officer)inPatrick Ritschel(Executive Officer, Director, Promoter)

Co-investorsPontifax Venture Capital Hatteras Venture Partners

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Attenua IFM TreSoleno Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.